

## Overview

### Useful For

Identifying specific mutations within the *BRCA1* and *BRCA2* genes known to be associated with response to PARP inhibitors and sensitivity to platinum-based therapy

This test is **not intended for** the evaluation of patients suspected of having inherited or germline *BRCA1* or *BRCA2* mutations.

### Genetics Test Information

This test uses targeted next-generation sequencing to evaluate for somatic mutations within the *BRCA1* and *BRCA2* genes. See [Targeted Genes and Methodology Details for BRCA1/2 Mutation Analysis](#) for details regarding the targeted gene regions evaluated by this test.

This test is performed to evaluate for somatic mutations within solid tumor samples. It **does not assess** for germline alterations within the genes listed.

### Additional Tests

Test Id	Reporting Name	Available Separately	Always Performed
SLIRV	Slide Review in MG	No, (Bill Only)	Yes

### Testing Algorithm

When this test is ordered, slide review will always be performed at an additional charge.

### Special Instructions

- [Tissue Requirements for Solid Tumor Next-Generation Sequencing](#)
- [Targeted Genes and Methodology Details for BRCA1/2 Mutation Analysis](#)

### Highlights

Evaluates formalin-fixed, paraffin-embedded tumor or cytology slides from patients with breast or ovarian cancer for gene mutations in the *BRCA1* and *BRCA2* genes to identify candidates for targeted therapy

### Method Name

Sequence Capture and Targeted Next-Generation Sequencing (NGS)

### NY State Available

Yes

## Specimen

---

**Specimen Type**

Varies

**Ordering Guidance**

Multiple oncology (cancer) gene panels are available. For more information see [Hematology, Oncology, and Hereditary Test Selection Guide](#).

**Necessary Information**

**A pathology report (final or preliminary), at minimum containing the following information, must accompany specimen for testing to be performed:**

1. Patient name
2. Block number-must be on all blocks, slides, and paperwork (can be handwritten on the paperwork)
3. Tissue collection date
4. Source of the tissue

**Specimen Required**

**This assay requires at least 20% tumor nuclei.**

- Preferred amount of tumor area with sufficient percent tumor nuclei: tissue 216 mm<sup>2</sup>
- Minimum amount of tumor area: tissue 36 mm<sup>2</sup>
- These amounts are cumulative over up to 10 unstained slides and must have adequate percent tumor nuclei.
- Tissue fixation: 10% neutral buffered formalin, not decalcified
- For specimen preparation guidance, see [Tissue Requirement for Solid Tumor Next-Generation Sequencing](#). In this document, the sizes are given as 4 mm x 4 mm x 10 slides as preferred: approximate/equivalent to 144 mm<sup>2</sup> and the minimum as 3 mm x 1 mm x 10 slides: approximate/equivalent to 36 mm<sup>2</sup>.

**Preferred:**

**Specimen Type:** Tissue block

**Collection Instructions:** Submit a formalin-fixed, paraffin-embedded tissue block with acceptable amount of tumor tissue.

**Acceptable:**

**Specimen Type:** Tissue slides

**Slides:** 1 Stained and 10 unstained

**Collection Instructions:** Submit 1 slide stained with hematoxylin and eosin and 10 unstained, nonbaked slides with 5-micron thick sections of the tumor tissue.

**Note:** The total amount of required tumor nuclei can be obtained by scraping up to 10 slides from the same block.

**Additional Information:** Unused unstained slides will not be returned.

**Specimen Type:** Cytology slides (direct smears or ThinPrep)

**Slides:** 1 to 3 Slides

**Collection Instructions:** Submit 1 to 3 slides stained and coverslipped with a preferred total of 5000 nucleated cells, or a minimum of at least 3000 nucleated cells.

**Note:** Glass coverslips are preferred; plastic coverslips are acceptable but will result in longer turnaround times.

**Additional Information:** Cytology slides will not be returned.

## Forms

If not ordering electronically, complete, print, and send an [Oncology Test Request](#) (T729) with the specimen.

## Specimen Minimum Volume

See Specimen Required

## Reject Due To

Specimens that have been decalcified (all methods) Specimens that have not been formalin-fixed, paraffin-embedded, except for cytology slides Extracted nucleic acid (DNA/RNA)	Reject
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------

## Specimen Stability Information

Specimen Type	Temperature	Time	Special Container
Varies	Ambient (preferred)		
	Refrigerated		

## Clinical & Interpretive

### Clinical Information

Studies have shown that somatic mutations in the *BRCA1* and *BRCA2* genes are clinically relevant in the selection of therapy for patients diagnosed with cancer. Patients with ovarian, breast, prostate, and pancreatic tumors that harbor a somatic *BRCA* mutation may respond to treatment with PARP (poly [ADP-ribose] polymerase) inhibitors and be sensitive to platinum-based therapy.

### Reference Values

An interpretive report will be provided.

### Interpretation

The interpretation of molecular biomarker analysis includes an overview of the results and the associated diagnostic,

---

prognostic, and therapeutic implications.

**Cautions**

This test cannot differentiate between somatic and germline alterations. Additional testing may be necessary to clarify the significance of results if there is a potential hereditary risk.

DNA variants of uncertain significance may be identified.

A negative result does not rule out the presence of a variant that may be present but below the limits of detection of this assay. The analytical sensitivity of this assay for sequence reportable alterations is 5% mutant allele frequency with a minimum coverage of 500X in a sample with 20% or more tumor content.

Point mutations and small deletion-insertion mutations will be detected in the *BRCA1* and *BRCA2* genes only. This test may detect single exon deletions but does not detect multiexon deletions, duplications, or genomic copy number variants.

Variant allele frequency (VAF) is the percentage of sequencing reads supporting a specific variant divided by the total sequencing reads at that position. In somatic testing, VAF should be interpreted in the context of several factors including, but not limited to: tumor purity/heterogeneity/copy number status (ploidy, gains/losses, loss of heterozygosity) and sequencing artifact/misalignment.(1,2)

Rare polymorphisms may be present that could lead to false-negative or false-positive results. The presence or absence of a variant may not predict response to therapy in all patients.

Test results should be interpreted in the context of clinical, tumor sampling, histopathological, and other laboratory data. If results obtained do not match other clinical or laboratory findings, contact the laboratory for discussion. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

Reliable results are dependent on adequate specimen collection and processing. This test has been validated on cytology slides and formalin-fixed, paraffin-embedded tissues; other types of fixatives are discouraged. Improper treatment of tissues, such as decalcification, may cause polymerase chain reaction failure.

**Supportive Data**

Performance Characteristics:

The limit of detection for calling a somatic variant (single nucleotide variants [SNV] and deletions-insertions [delins, formerly indels]) is 5% variant allele frequency and having at least 500x deduplicated coverage.

Verification studies demonstrated concordance between this test and the reference method for detection of SNV and delins is 99.7% (699/701) and 96.6% (226/234) of variants, respectively. Concordance for the detection of delins was 98.9% (186/188) in variants 1-10 base pairs (bp) in size, 95.8% (23/24) in variants 11-50 bp in size, and 88.9% (8/9) in variants 51-200 bp in size.

**Clinical Reference**

1. Strom SP. Current practices and guidelines for clinical next-generation sequencing oncology testing. *Cancer Biol Med.* 2016;13(1):3-11. doi:10.28092/j.issn.2095-3941.2016.0004

2. Spurr L, Li M, Alomran N, et al. Systematic pan-cancer analysis of somatic allele frequency. *Sci Rep*. 2018;8(1):7735. Published 2018 May 16. doi:10.1038/s41598-018-25462-0
3. US Food and Drug Administration (FDA): Table of Pharmacogenomic Biomarkers in Drug Labeling. Updated February 10, 2023, Accessed July 31, 2023. Available at [www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling](http://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling)
4. Petrucelli N, Daly MB, Pal T: BRCA1- and BRCA2-associated hereditary breast and ovarian cancer. In: Adam MP, Everman DB, Mirzaa GM, et al, eds. *GeneReviews* [Internet]. University of Washington, Seattle; 1998. Updated May 26, 2022. Accessed July 31, 2023. Available at [www.ncbi.nlm.nih.gov/books/NBK1247/](http://www.ncbi.nlm.nih.gov/books/NBK1247/)
5. Tung, NM, Garber, JE. BRCA1/2 testing: therapeutic implications for breast cancer management. *Br J Cancer*. 2018;119(2):141-152. doi: 10.1038/s41416-018-0127-5

## Performance

### Method Description

Next-generation sequencing is performed to evaluate the presence of a mutation in all coding regions of the *BRCA1* and *BRCA2* genes. See [Targeted Genes and Methodology Details for BRCA1/2 Mutation Analysis](#) for details regarding the targeted gene regions evaluated by this test. (Unpublished Mayo method)

A pathology review and macro dissection to enrich for tumor cells are performed prior to slide scraping

### PDF Report

No

### Day(s) Performed

Monday through Friday

### Report Available

12 to 20 days

### Specimen Retention Time

FFPE tissue block: Unused portions of blocks will be returned within 10-14 days after testing is complete; FFPE tissue/cytology slides: Unused slides are stored indefinitely; Digital images are obtained and stored for all slides used in testing.

### Performing Laboratory Location

Rochester

## Fees & Codes

### Fees

- Authorized users can sign in to [Test Prices](#) for detailed fee information.

- Clients without access to Test Prices can contact [Customer Service](#) 24 hours a day, seven days a week.
- Prospective clients should contact their account representative. For assistance, contact [Customer Service](#).

### Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

### CPT Code Information

88381 - Microdissection, manual  
81163

### LOINC® Information

Test ID	Test Order Name	Order LOINC® Value
BRCAT	BRCA1/2 Mutation Analysis, Tumor	59041-4

Result ID	Test Result Name	Result LOINC® Value
617889	Result	82939-0
617890	Interpretation	69047-9
617891	Additional Information	48767-8
617892	Specimen	31208-2
617893	Tissue ID	80398-1
617894	Method	85069-3
617895	Disclaimer	62364-5
617896	Released By	18771-6